To The Moon

1001 ET - The steep selloff in Sarepta Therapeutics shares following the death of a patient who received its Elevidys gene therapy is likely overdone, Mizuho's Uy Ear says in a brief note. Mizuho says while acute liver injury is a known side effect of Elevidys, this is the first case of acute liver failure leading to death after more than 800 patients have been treated, and that the individual who died had a recent cytomegalovirus infection, which can damage the liver. Mizuho, with an outperform rating and $190 price target on Sarepta, says it still see the Elevidys benefit/risk profile as positive. Sarepta tumbles 23% to $78.